MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer

Imported from official source

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).

This version

Version
1 of 1
Recorded
November 11, 2026 17:02
Change
Initial
Content hash
b4dc13d2cad2dfde72b67422fb63ccc5
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.